• The impact of N-linked glycosylation on ADAMTS-13 function has not been fully explored.
• The impact of N-linked glycosylation on ADAMTS- 13 function has not been fully explored.
• The activity of glycan modified ADAMTS-13 was investigated under static and shear stress conditions. • Terminal sialic acid on the metalloprotease domain glycans are important for ADAMTS-13 activity.
• The CUB domain glycans modulate ADAMTS-13 activity.
Summary. Background: ADAMTS-13 activity can be regulated by its conformation, whereby interactions between the C-terminal CUB domains and the spacer domain maintain ADAMTS-13 in a closed conformation. ADAMTS-13 contains 10 N-linked glycans, with four sites present in theTSP2 through to CUB domains that may contribute to its conformation. Objectives/Methods: We hypothesized that glycosylation contributes to ADAMTS-13 conformation and function. The proteolytic activity of glycanmodified ADAMTS-13 was assessed under static and shear stress conditions. Results: Enzymatic removal of terminal silaic acid or entire N-linked glycan chains decreased activity against FRETS-VWF73 at pH 7.4 and against fulllength von Willebrand factor (VWF) under shear stress. Using truncated ADAMTS-13, we demonstrated that this was attributable to loss of sialic acid from the glycans in the metalloprotease domain and an effect of N-linked glycosylation in the TSP2 through to CUB domains. Mutation of the N-linked glycan sites in the MDTCS domains reduced or abolished protein expression. However, the N707Q, N828Q, N1235Q and N1354Q (TSP2, TSP4, CUB1, and CUB2 domains, respectively) variants were expressed normally. Interestingly, the N707Q and N828Q variants showed reduced activity against FRETS-VWF73, but normal activity under flow conditions. In contrast, the N1235Q and N1354Q variants had enhanced activity against FRETS-VWF73 and VWF under shear stress.
Immunoprecipitation experiments confirmed that loss of N-linked glycans in the CUB domains significantly reduced the interaction with the spacer domain and enhanced binding to the 6A6 anti-ADAMTS-13 antibody, which recognizes a cryptic epitope in the metalloprotease domain. Conclusions: Together, these data demonstrate that the N-linked glycans of ADAMTS-13 play a crucial role in regulating ADAMTS-13 activity.
Keywords: ADAMTS-13; glycosylation; proteolysis; thrombosis; von Willebrand factor. Background ADAMTS-13 is responsible for the proteolysis of von Willebrand factor (VWF) by cleavage at a specific site within the VWF A2 domain [1, 2] . This reduces the multimeric size of VWF and regulates its hemostatic function within the circulation. Deficiency of ADAMTS-13 caused by a genetic defect or an autoantibody results in the rare but potentially fatal condition thrombotic thrombocytopenic purpura, characterized by the presence of ultralarge VWF multimers and widespread microvascular occlusions [3] . Cleavage of VWF by ADAMTS-13 is a multistep process in which the C-terminal domains of ADAMTS-13 distal to the spacer domain first dock the ADAMTS-13 molecule to the C-terminal D4-CK domains of VWF [4, 5] . Subsequently, unfolding of VWF presents binding sites in the VWF A2 domain for ADAMTS-13, and ultimately allows cleavage of the Y1605-M1606 scissile bond in the A2 domain [6] [7] [8] [9] [10] . Thus, the cleavage of VWF by ADAMTS-13 requires the substrate to undergo a conformational change to allow access to the cleavage site. In vivo, this may result from VWF binding to collagen or platelets, exposure of the VWF molecule to shear stress, or some combination of these factors [11] [12] [13] . In vitro, the unfolding can be mimicked by the use of urea or reproduced in various forms of shear-based assays [1, 14, 15] . Recent studies have shown that ADAMTS-13 can undergo complementary conformational changes [16, 17] . Muia et al. showed that binding of ADAMTS-13 to isolated D4CK domains of VWF enhanced its activity against the FRETS-VWF73 substrate [16] , and South et al. demonstrated direct interaction of the CUB domains with the spacer domain [17] . Furthermore, using electron microscopy, both studies found that ADAMTS-13 exists in two conformations, a closed conformation and an open conformation, in which the ADAMTS-13 molecule is more active, and this is promoted by binding of the D4CK domains of VWF to the ADAMTS-13 CUB domains.
ADAMTS-13 is a modular molecule comprising a signal peptide, a propeptide, a metalloprotease (MP) domain, a disintegrin domain, a thrombospondin type 1 repeat (TSP), a cysteine-rich region, a spacer domain, seven additional thrombospondin repeats (nos. [2] [3] [4] [5] [6] [7] [8] , and two CUB (complement component Clr/Cls, Uegf, bone morphogenetic protein 1) domains [18] . Like that of its VWF substrate, a significant proportion of the final molecular mass of ADAMTS-13 is attributable to glycan residues, with 10 predicted N-linked glycosylation sites and potential O-fucosylation and C-mannosylation sites [19] . Mass spectroscopic analysis of plasma ADAMTS-13 has recently confirmed that nine of the 10 possible N-linked glycosylation sites are occupied, and has identified six O-fucosylation sites, two Cmannosylation sites, and six O-linked glycosylation sites [19, 20] . The roles of the sugar moiety of ADAMTS-13 are not fully defined, although it has been previously shown that O-fucosylation is required for proper secretion of ADAMTS-13 [21] , and Zhou et al. showed that N-linked glycosylation at N146 in the MP domain, N552 in the spacer domain and N828 in the TSP8 domain are also required for effective secretion [22] . Furthermore, the same study demonstrated that ADAMTS-13 containing only high-mannose glycans, rather than fully processed glycan chains, had reduced activity against full-length VWF (FL-VWF) under static conditions [22] . However, this study did not provide a mechanism for this effect, did not examine cleavage of VWF under shear stress, and, importantly, did not explore the role of glycans in the CUB domains. Because it is now clear that the CUB domains play a critical role in the regulation of ADAMTS-13 function and that this function is also dependent on glycan structure, we have performed a detailed investigation into the role of N-linked glycosylation in mediating ADAMTS-13 conformation and function.
Materials and methods

Protein expression and purification
Recombinant full-length ADAMTS-13, the MDTCS, MD and CUB1/2 truncations, plasma-derived VWF and recombinant VWF-D4CK were all prepared as previously described [10, 17, 23, 24] . ADAMTS-13 variants lacking glycosylation at specific sites were created with the QuickChange site-directed mutagenesis kit (Stratagene, Cambridge, UK), changing asparagines to glutamine. These were expressed in HEK293T cells, and concentrated with Amicon Ultra centrifuge concentrators (molecular mass cut-off of 100 kDa) (Peterbrough, UK). The concentration of ADAMTS-13 in the conditioned media was determined with an in-house ADAMTS-13 ELISA [25] . An MDTCS construct with a C-terminal FLAG tag was generated with full-length ADAMTS-13 as the template. Primers were designed with the NEBuilder assembly tool, and the NEBuilder HiFi DNA assembly kit was used to amplify the sequence for MDTCS and clone it into the p3XFLAG-CMV-14 mammalian expression vector. MDTCS-FLAG was expressed in HEK293T cells and purified by the use of magnetic anti-M2-FLAG beads (Sigma, Gillingham, UK).
Glycan modification of ADAMTS-13
Recombinant ADAMTS-13 (rADAMTS-13) at a final concentration 300 nM was incubated overnight at 37°C with either 10 U of PNGase-F or 1 U of a2-3,6,8,9-neuraminidase. ADAMTS-13 was then centrifuged (3500 9 g) in Amicon Ultra centrifuge concentrators with a molecular mass cut-off of 100 kDa to remove PNGase-F or neuraminidase, and dialysed against 20 mM Tris and 10 mM CaCl 2 (pH 7.4). A control sample was processed in the same way, and all proteins were quantified by ELISA before use. The extent of glycan modification was assessed with a lectin ELISA as previously described, with concanavalin A (ConA) to detect N-linked glycan chains and elderberry bark lectin (EBL) to detect terminal sialic acid residues [26, 27] .
Cleavage assays
The proteolytic activities of ADAMTS-13 and its variants were assessed with the FRETS-VWF73 assay, static cleavage assays using urea, and shear-based assays using a vortex mixer, all as previously described. [15, 28] . Cleavage of VWF by ADAMTS-13 was also assessed with an in vitro flow chamber model, as previously described [15] . In brief, Ibidi l-slideVI 0.1 flow chamber slides were coated overnight with 100 lg mL À1 human type III collagen (Southern Biosciences, Cambridge, UK), and then blocked with 2% bovine serum albumin. Plasma-free blood (PFB) was prepared as previously described, and platelets were rendered fluorescent by the addition of 1 lM DiOC 6 [29] . PFB was supplemented with 7 lg mL À1 VWF and rADAMTS-13 or it variants, and perfused over the collagen surface for 5 min at 1500 s À1 ; platelet capture was recorded in real time. Platelet surface coverage was determined with IMAGEJ, as previously described.
Analysis of the MDTCS-CUB interaction by coimmunoprecipitation
Recombinant CUB1/2 domain containing a C-terminal myc tag (final concentration 100 nM) was incubated with 10 U of Remove-iT PNGase-F, which is linked to a chitin-binding domain (NEB, Hitchin, UK), overnight at 37°C. Remove-iT PNGase-F was removed by incubation with magnetic chitin beads. Control samples not digested with PNGase-F were treated in the same way. Following PNGase-F digestion and removal, protein was requantified with a bicinchoninic acid assay. Control or PNGase-F-treated CUB1/2 (50 nM) was incubated with 25 nM MDTCS-FLAG in 20 mM Tris and 50 mM NaCl (pH 7.4) for 60 min at 37°C, with up-and-over mixing. During the incubation, 30 lL of magnetic anti-M2-FLAG beads were blocked with 5% powdered milk diluted in phosphate-buffered saline, and then used to immunoprecipitate the MDTCS-CUB1/2 complexes for 30 min at room temperature. The beads were then washed three times with Trisbuffered saline, and proteins were eluted with 2 9 LDS loading buffer supplemented with 7% v/v b-mercaptoethanol and heating for 15 min at 70°C. Proteins were analyzed by SDS-PAGE, followed by western blotting and probing with anti-myc-horseradish peroxidase antibodies to detect the myc-tagged CUB1/2 domain. Binding of ADAMTS-13 to the 6A6 antibody was performed as previously described [30] . Statistical analysis was performed with GRAPHPAD PRISM Student's t-test.
Results
N-linked glycosylation and sialylation of ADAMTS-13 determines activity against VWF in an assay-dependent manner
To investigate the effects of ADAMTS-13 N-linked glycans on its ability to proteolyse VWF, ADAMTS-13 devoid of N-linked glycans was prepared by digestion with PNGase-F (PNG-AD13), and ADAMTS-13 lacking terminal sialic acid residues was prepared by digestion with a broad-spectrum neuraminidase (Neu-AD13). Lectin binding analysis with ConA and EBL demonstrated complete removal of entire N-linked glycan chains and terminal sialic residues, respectively ( Fig. S1 ). Initially, cleavage assays were performed with the FRETS-VWF73 substrate. This assay is normally carried out pH 6.0; however, it has recently been shown that ADAMTS-13 proteolysis of this substrate is affected by pH, owing to conformational activation [16] . When used to cleave the FRETS-VWF73 substrate at pH 6.0, both Neu-AD13 and PNG-AD13 digested the substrate to a similar extent to wild-type ADAMTS-13 (WT-AD13) (Fig. 1A) . Interestingly, when the reaction was performed at physiologic pH (7.4), Neu-AD13 showed significantly reduced activity as compared with WT-AD13, and the activity of PNG-AD13 was significantly lower still (Fig. 1B,C) . To further determine the activity of glycan-modified ADAMTS-13, VWF cleavage assays were performed against full-length VWF (FL-VWF) under static conditions in the presence of urea, and using a high-speed vortex mixer to generate mechanical shear stress. In the presence of urea, there was no significant difference between the abilities of Neu-AD13 and PNG-AD13 to cleave VWF multimers (Fig. 1D ). Interestingly, under mechanical shear stress conditions, both Neu-AD13 and PNG-AD13 showed reduced activity against VWF (Fig. 1E ). However, unlike the cleavage of FRETS-VWF73 at pH 7.4, no difference was seen in the loss of activity between Neu-AD13 and PNG-AD13.
N-linked glycosylation and sialylation of ADAMTS-13 is required for full activity under shear stress
To determine ADAMTS-13 function in a more physiologic setting, we used a flow assay model to quantify the ability of glycan-modified ADAMTS-13 to reduce VWF-mediated platelet capture to a collagen surface under high shear stress. In keeping with our previously published data, when PFB supplemented with VWF and WT-AD13 was perfused over a collagen surface, the extent of platelet capture was reduced as compared with PFB devoid of ADAMTS-13 ( Fig. 2A ) [15] . Significantly, Neu-AD13 and PNG-AD13 were equally less effective than WT-AD13 in reducing VWF-mediated platelet capture, suggesting that sialic acid present on the N-linked glycans of ADAMTS-13 is critical for proper enzyme function ( Fig. 2A,B) .
Sialylation of N-linked glycans in the MP domain are required for proper ADAMTS-13 function
To determine whether the N-linked glycans and terminal sialic residues of ADAMTS-13 modulate its function by altering its enzymatic activity or its substrate binding, we expressed ADAMTS-13 MDTCS and MD constructs, treated these similarly with neuraminidase or PNGase-F, and measured their activity against FRETS-VWF73. Both neuraminidase-treated MDTCS (Neu-MDTCS) and PNGase-F-treated MDTCS (PNG-MDTCS) had reduced activity against FRETS-VWF73 at pH 7.4 as compared with normally glycosylated controls, this time with no difference between Neu-AD13 and PNG-AD13 (Fig. 3B) . Similarly, neuraminidase-treated MD (Neu-MD) and PNGase-F-treated MD (PNG-MD) had equally reduced activity against FRETS-VWF73 (Fig. 3B) . To further confirm this, we examined the cleavage of VWF under shear stress, and, similarly to what we observed with fulllength ADAMTS-13, Neu-MDTCS and PNG-MDTCS were equally less effective at reducing VWF-mediated platelet capture to collagen under flow conditions (Fig. 3C) . The MD construct was unable to digest VWF in the flow assay, most likely because of its low affinity for VWF (data not shown). As the MD construct contains only two N-linked glycosylation sites (N142 and N146 in the MP domain), and removal of the terminal sialic acid reduces activity to the same extent as removal of the entire glycan chains, we conclude that sialylation of either or both of these glycans is required for proper ADAMTS-13 proteolytic activity.
N-linked glycosylation of ADAMTS-13 modulates the conformation of ADAMTS-13
The observations that PNG-AD13 showed a greater reduction in activity against FRETS-VWF73 than Neu-AD13, and that this difference was diminished when C-terminally truncated ADAMTS-13 variants were used, suggested that total deglycosylation of full-length ADAMTS-13 had a further effect on ADAMTS-13 function in addition to the loss of sialic acid from the MP domain glycans. To investigate this further, we performed static plate binding assays to determine the binding of glycan-modified ADAMTS-13 to the VWF A2 domain. Both Neu-AD13 and PNG-AD13 bound to the A2 domain with similar affinity to unmodified control ADAMTS-13 (Con-AD13), suggesting that, first, the reduced activity of Neu-AD13 is not attributable to altered substrate binding, and second, loss of the N-linked glycan chains does not alter the ability of ADAMTS-13 to bind to VWF, at least under static conditions (Fig. 4A ). It has previously been shown that incubation of fulllength ADAMTS-13 with the D4 domain of VWF induces a conformational change in ADAMTS-13 that enhances its activity against FRETS-VWF73 by 'activating' the ADAMTS-13 molecule [16] . We therefore preincubated WT-AD13 or PNG-AD13 with VWF-D4CK, and determined the effect on FRETS-VWF73 cleavage. Consistent with previously published data, preincubation with VWF-D4CK enhanced the activity of ADAMTS-13 against FRETS-VWF73 (Fig. 4B) . Interestingly, VWF-D4CK also enhanced the activity of PNG-AD13, but only to the same level as that of ADAMTS-13 that had not been preactivated. The addition of increasing concentrations of VWF-D4CK could not further enhance the activity of PNG-AD13, which was presumably limited by the loss of sialic acid from the MD domain (Fig. 4B) . To confirm this, we activated Neu-AD13 with VWF-D4CK, and assessed its cleavage activity against FRETS-VWF73. As expected, this enhanced the activity of Neu-AD13, but not to the same extent as WT-AD13 activated with VWF-D4CK (Fig. 4B) . These data suggest that the C-terminal domains of VWF are able to properly interact with the C-terminal domains of both Neu-AD13 and PNG-AD13 to evoke a conformational change and enhance activity.
Glycosylation of the C-terminal domains of ADAMTS-13 determines activity
As the reduced activity of PNG-AD13 against FRETS-VWF73 could be enhanced by the addition of VWF-D4CK, we hypothesized that removal of the C-terminal glycans of ADAMTS-13 rendered the molecule less active, potentially by altering interactions between the N-terminal and C-terminal parts of the molecule. Because PNGase-F treatment non-selectively removes all glycans, we prepared ADAMTS-13 mutants lacking glycosylation at each of the 10 N-linked glycan sites. Mutation of the glycosylation sites in the MP domain through to the spacer domain resulted in either totally abolished or significantly reduced secretion of ADAMTS-13, indicating that these sites are essential for proper protein folding and processing within the cell (Fig. S2) . Mutation of the glycosylation sites in the TSP2 (N707Q), TSP5 (N828Q), CUB1 (N1235Q) and CUB2 (N1354Q) domains did not significantly affect secretion. Interestingly, both the N707Q mutant and the N828Q mutant (TSP2 and TSP5) had reduced activity against FRETS-VWF73, with the N828Q mutant showing the greater reduction in activity (Fig. 5A,B) . However, both mutants had normal activity under shear stress conditions (Fig. 5C ), and were activated by VWF-D4CK to the same extent as WT-AD13 (Fig. 5D) . Intriguingly, and in contrast to the N707Q and N828Q mutants, mutation of the N-linked glycans in the CUB domains (N1235Q and N1354Q) resulted in approximately two-fold enhanced activity against FRETS-VWF73 (Fig. 5A,B) . Significantly, both the N1235Q mutant and the N1354Q mutant were also more effective at cleaving VWF under flow conditions, highlighting their gain-of-function (GoF)-like activity (Fig. 6A,B) . As the overall effect of PNGase-F treatment is to reduce cleavage, it appears the effect of the TSP glycans is dominant, at least in the FRETS-VWF73 assay.
N-linked glycosylation of the CUB domains is required for the spacer-CUB interaction
As mutation of the glycosylation sites in the CUB domains enhanced the activity of ADAMTS-13, we hypothesized that these molecules are already active, possibly because of altered interactions between the CUB and spacer domains. Consistent with this, when cleavage of FRETS-VWF73 was performed at pH 6.0, the enhancing effect of the N1235Q and N1354Q mutations was lost (Fig. 7A) . Furthermore, at pH 7.4, the addition of VWF-D4CK could not further enhance the activity of the N1235Q and N1354Q mutants (Fig. 7B ), suggesting that these molecules had already adopted the open 'active' conformation. Moreover, both mutants showed enhanced binding to the anti-ADAMTS-13 6A6 antibody, which preferentially binds to 'active' ADAMTS-13, confirming that they are in a more open, active conformation (Fig. 7C) . Finally, immunoprecipitation experiments confirmed that isolated CUB domains devoid of N-linked glycosylation had reduced binding to the ADAMTS-13 spacer domain, confirming that one or both of the N-linked glycan sites in the CUB domain are essential for the interaction between the CUB and spacer domains, and hence modulate the inactive and active conformations of ADAMTS-13 (Fig. 7D ).
Discussion
Although a previous study has addressed the functional significance of the ADAMTS-13 N-linked glycans, the activity against VWF was not investigated under shear stress conditions, and no data were provided on the role of the glycans in the CUB domain, which have subsequently been shown to regulate ADAMTS-13 activity. In the present study, we have re-evaluated the effect of N-linked glycosylation on ADAMTS-13 expression and function.
Removal of terminal sialic acid residues or whole N-linked glycan chains resulted in reduced ADAMTS-13 function, when activity was assessed at physiologic pH (in the case of the FRETS-VWF73 assay) and under shear stress conditions. In the case of the FRETS-VWF73 assay, Muia et al. have recently demonstrated that pH alters the cleavage of this substrate by full-length ADAMTS-13, reflecting its conformation. Interestingly, when used to digest FRETS-VWF73 at pH 7.4, PNG-AD13 had reduced activity as compared with Neu-AD13; however, this was not observed under shear stress, with both Neu-AD13 and PNG-AD13 being equally less active, suggesting that loss of sialic acid was responsible for the reduction in activity. The pH sensitivity is consistent with studies showing that loss of sialic acid can significantly alter the protein pI [31] . Some of these observations are consistent with the study of Zhou et al., in which PNG-AD13 showed normal activity against FL-VWF in the presence of guanidine chloride [22] . Similarly, we did not observe any effect of glycan removal on ADAMTS-13 activity when assays were performed with urea. It is likely that denaturants alter the conformation of ADAMTS-13 as well as that of VWF. Interestingly, Zhou et al. did observe decreased activity with ADAMTS-13 lacking complex glycans (and therefore sialic acid) under static conditions. In our assays, sialic acid removal did not affect activity at pH 6.0 or in the presence of urea. It is not fully understood why this is the case, but we have previously observed the ability of high urea concentrations to obscure the effects of VWF glycosylation on susceptibility to ADAMTS-13 cleavage [32] , and mutation of the VWF O-linked glycans resulted in different effects on cleavage in static and flow-based assays [15] .
Nonetheless, assays performed under shear stress provide a more physiologic measure of ADAMTS-13 activity, and it is clear that appropriate reaction conditions are essential for assessing ADAMTS-13 function.
To investigate the roles of specific glycan modifications on ADAMTS-13 function, we used truncated ADAMTS-13 molecules: MDTCS and MD. Against FRETS-VWF73, Neu-MDTCS, PNG-MDTCS, Neu-MD and PNG-MD were equally less effective than Con-AD13 in digesting the substrate. As there are two N-linked glycans in the MP domain, we conclude that sialylation of one or both of these glycans is essential for proper ADAMTS-13 function. This is in keeping with the study of Zhou et al., in which an ADAMTS-13 molecule composed of the MP domain through to the TSP1 domain was less active when devoid of complex glycans (i.e. lacking sialic acid). Zhou et al. also demonstrated that the N146 mutation but not the N142 mutation reduced ADAMTS-13 activity; however, we were unable to observe any secretion of the N146Q mutant, and the N142Q mutant showed significantly reduced secretion, indicating that both of these glycans are crucial for proper folding within the cell. We were therefore unable to analyze the effects of these individual mutations on ADAMTS-13 function.
It is unclear how terminal sialic acid residues modulate the function of the MP domain. Both N-linked glycosylation sites in the MP domain (N142 and N146) are located in close spatial proximity to the high-affinity calcium-binding site mapped to E184, D187, and E212. Moreover, both glycans have been shown to present sialic acid residues [20] . Sialic acid has been previously shown to have calcium-binding properties, and may therefore facilitate efficient binding of calcium to ADAMTS-13 [33] [34] [35] .
These observation have potential clinical implications. It has been shown that release of bacterial neuraminidase in sepsis can result in significant desialylation of VWF and platelets, resulting in increased clearance [36] . If ADAMTS-13 were to be similarly desialylated, then we would predict a reduction in ADAMTS-13 activity. On the other hand, protein sialylation is generally increased in liver disease, which conceivably may also alter ADAMTS-13 function [37] . In parallel, an effect on sialylation is seen in other diseases, such primary pulmonary hypertension, in which VWF sialic acid levels are decreased [38] , a modification that is known to VWF alter susceptibility to ADAMTS-13 cleavage [26] . In the FRETS-VWF73 assay (at pH 7.4), PNGase-F treatment was able to reduce cleavage additionally to desialylation, but only when full-length ADAMTS-13 was used, suggesting that the effect was linked to changes in conformation related to the closed and open conformations of ADAMTS-13. We hypothesized that PNG-AD13 molecules more readily adopt the closed conformation, which reduces their activity in the FRETS-VWF73 assay. However, this can be overcome by increasing concentrations of VWF-D4CK.
Similarly, in shear-based assays against FL-VWF, the unraveling of VWF exposes binding sites in the A2 binding site that compete with the CUB domain for the spacer domain, and again activate the ADAMTS-13 molecule. As expected, the activity of Neu-AD13 could also be enhanced by the addition of VWF-D4CK, but not to the level of Con-AD13, owing to the effect of sialic acid being lost from the MP glycans. These data confirm that, in addition to loss of sialic acid, removal of N-linked glycan chains from ADAMTS-13 favors its inactive closed conformation, but this does not prevent physiologic activation of the molecule by the D4CK region of VWF.
To identify the specific glycans responsible, we expressed ADAMTS-13 glycosylation variants. Interestingly, the majority of the variants with mutations located in the N-terminal domains of ADAMTS-13 had either abolished or reduced secretion, which is in contrast to Zhou et al., who found that only two glycan mutants, N146Q and N828Q, had reduced secretion. The reason for this disparity is not clear; however, Zhou et al. analyzed expression following concentration of the expression medium and western blotting, whereas we performed an ADAMTS-13 ELISA on non-concentrated samples [22] . The C-terminal domains of ADAMTS-13 contain four N-linked glycan sites: N707 in the TSP1/2 domain, N828 in the TSP1-4 domain, and N1235 and N1354 in the CUB1 and CUB2 domains, respectively. Interestingly both the N707Q mutation and the N828Q mutation caused decreased activity against FRETS-VWF73, but the molecules had full activity in the in vitro flow assay. In keeping with our previous argument, the FRETS-VWF73 results suggest that loss of these glycans favors the closed conformation of ADAMTS-13, but this is overcome upon activation with the VWF D4 domain. A recent study has demonstrated that ADAMTS-13 has three linker regions, with two of these being located between (i) TSP1/2 and TSP1-3, and (ii) TSP1-4 and TSP1-5. It was shown that these linker regions provide flexibility to the ADAMTS-13 molecule, allowing it to adopt its closed conformation, and that their deletion resulted in ADAMTS-13 molecules favoring the more open active conformation [30] . On the basis of the primary amino acid sequence, N707 and N828 lie close to these linker regions, and their bulky configurations may therefore provide a degree of rigidity to the surrounding region. Loss of glycosylation renders the molecule more flexible and able to adopt its closed (inactive) conformation.
Conversely, mutation of the N-linked glycan sites in the CUB domains enhanced the activity against FRETS-VWF73, and this was not increased by the addition of VWF-D4CK. Significantly, the increased activity was retained under shear stress. The FRETS-VWF73 data imply that removal of glycans from the CUB domains allows ADAMTS-13 to assume its active conformation more readily. Previously, GoF mutations in the spacer domain (R568K/F592Y/R660K/Y661F/Y665F) have been shown to abolish binding to CUB domains [17, 39] . In an analogous fashion, immunoprecipitation experiments demonstrated that CUB domains lacking N-linked glycans had significantly reduced binding to the spacer domain, resulting in increased activity. As with the R568K/F592Y/R660K/Y661F/Y665F GoF variant, the enhanced activity may be attributable to the loss of Our data reveal an important and previously unrecognized role for N-linked glycosylation in promoting the CUB-spacer interaction. The effect was confirmed by demonstrating that the N1235Q and N1354Q mutants also had increased binding to the previously described 6A6 anti-ADAMTS-13 antibody, which binds a cryptic epitope in the MP domain. Further work is required to understand how the CUB glycans facilitate the interaction with the spacer domain. Hypothetically, they may do this by either promoting the correct configuration of the CUB domains or by directly mediating the interaction.
In conclusion, this study demonstrates the importance of N-linked glycosylation for proper ADAMTS-13 function under static and, importantly, shear stress conditions. Sialylation of the MP domain is required for proper proteolytic function, and glycosylation of the TSP2 and TSP4 domains and CUB domains is a critical modulator of ADAMTS-13 conformation, with glycosylation of the CUB domains being required for the interaction with the spacer domain. preparing this manuscript. This work is supported by grants from the British Heart Foundation.
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